Market Cap | 179.78M | P/E | - | EPS this Y | 26.10% | Ern Qtrly Grth | - |
Income | -80.55M | Forward P/E | -1.88 | EPS next Y | -5.80% | 50D Avg Chg | 5.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 50.00% |
Dividend | N/A | Price/Book | 1.30 | EPS next 5Y | - | 52W High Chg | -49.00% |
Recommedations | 1.60 | Quick Ratio | 6.67 | Shares Outstanding | 56.50M | 52W Low Chg | 196.00% |
Insider Own | 2.27% | ROA | -40.41% | Shares Float | 44.48M | Beta | 2.49 |
Inst Own | 95.24% | ROE | -83.38% | Shares Shorted/Prior | 5.86M/6.01M | Price | 3.49 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 4,257,912 | Target Price | 14.83 |
Oper. Margin | - | Earnings Date | Nov 4 | Volume | 369,175 | Change | -5.68% |
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
HC Wainwright & Co. | Buy | Sep 24, 24 |
Piper Sandler | Overweight | Sep 23, 24 |
HC Wainwright & Co. | Buy | Sep 18, 24 |
Wedbush | Outperform | Sep 10, 24 |
HC Wainwright & Co. | Buy | Sep 4, 24 |
Wedbush | Outperform | Aug 7, 24 |
Raymond James | Outperform | Jul 31, 24 |
Piper Sandler | Overweight | Jul 3, 24 |
HC Wainwright & Co. | Buy | Jun 7, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Behbahani Ali | Director Director | Jul 05 | Buy | 5.00 | 1,000,000 | 5,000,000 | 4,448,757 | 07/06/23 |
BIOTECH GROWTH N V | 10% Owner 10% Owner | Jun 27 | Buy | 5.4914 | 1,740,000 | 9,555,036 | 7,117,839 | 06/29/23 |
BIOTECH GROWTH N V | 10% Owner 10% Owner | Oct 27 | Buy | 2.03 | 364,652 | 740,244 | 5,278,038 | 10/31/22 |
BIOTECH GROWTH N V | 10% Owner 10% Owner | Apr 18 | Buy | 3.27 | 300,000 | 981,000 | 4,288,402 | 04/20/22 |
BIOTECH GROWTH N V | 10% Owner 10% Owner | Apr 12 | Buy | 3.5 | 252,556 | 883,946 | 3,988,402 | 04/14/22 |
Hatzis-Schoch Brent | See Remarks See Remarks | Apr 13 | Option | 3.2 | 4,078 | 13,050 | 12,478 | 04/13/21 |
Hatzis-Schoch Brent | See Remarks See Remarks | Apr 13 | Sell | 25 | 4,078 | 101,950 | 8,400 | 04/13/21 |
Roberts Christopher D. | Chief Scientific Off.. Chief Scientific Officer | Mar 04 | Option | 10.86 | 2,500 | 27,150 | 5,700 | 03/04/21 |
Roberts Christopher D. | Chief Scientific Off.. Chief Scientific Officer | Mar 04 | Sell | 26.21 | 2,500 | 65,525 | 3,200 | 03/04/21 |
Hatzis-Schoch Brent | See Remarks See Remarks | Feb 12 | Sell | 27.43 | 4,078 | 111,860 | 8,400 | 02/12/21 |
Hatzis-Schoch Brent | See Remarks See Remarks | Feb 12 | Option | 3.2 | 4,078 | 13,050 | 12,478 | 02/12/21 |
Roberts Christopher D. | Chief Scientific Off.. Chief Scientific Officer | Feb 04 | Option | 10.86 | 2,500 | 27,150 | 5,700 | 02/04/21 |
Roberts Christopher D. | Chief Scientific Off.. Chief Scientific Officer | Feb 04 | Sell | 25.35 | 2,500 | 63,375 | 3,200 | 02/04/21 |
Hatzis-Schoch Brent | See Remarks See Remarks | Jan 14 | Option | 7.03 | 11,578 | 81,393 | 19,978 | 01/14/21 |
Hatzis-Schoch Brent | See Remarks See Remarks | Jan 14 | Sell | 32.49 | 11,578 | 376,169 | 8,400 | 01/14/21 |
Leggett Thomas | Chief Financial Offi.. Chief Financial Officer | Jan 11 | Option | 10.86 | 3,000 | 32,580 | 3,000 | 01/11/21 |
Leggett Thomas | Chief Financial Offi.. Chief Financial Officer | Jan 11 | Sell | 33.94 | 3,000 | 101,820 | 01/11/21 | |
Roberts Christopher D. | Chief Scientific Off.. Chief Scientific Officer | Jan 06 | Option | 10.86 | 2,500 | 27,150 | 5,700 | 01/06/21 |
Roberts Christopher D. | Chief Scientific Off.. Chief Scientific Officer | Jan 06 | Sell | 31.54 | 2,500 | 78,850 | 3,200 | 01/06/21 |
Epstein David M. | See Remarks See Remarks | Jan 06 | Option | 6.42 | 3,000 | 19,260 | 708,423 | 01/06/21 |
Epstein David M. | See Remarks See Remarks | Jan 06 | Sell | 31.39 | 12,000 | 376,680 | 696,423 | 01/06/21 |
Bolzon Bradley J PhD | Director Director | Dec 01 | Sell | 33.65 | 10,393 | 349,724 | 874,099 | 12/01/20 |
Bolzon Bradley J PhD | Director Director | Nov 23 | Sell | 33.01 | 130,017 | 4,291,861 | 4,818,600 | 11/23/20 |
Bolzon Bradley J PhD | Director Director | Nov 19 | Sell | 33.07 | 4,730 | 156,421 | 4,933,454 | 11/19/20 |
Bolzon Bradley J PhD | Director Director | Nov 17 | Sell | 33.62 | 4,700 | 158,014 | 4,937,632 | 11/17/20 |
Bolzon Bradley J PhD | Director Director | Nov 13 | Sell | 34.34 | 15,598 | 535,635 | 4,941,784 | 11/13/20 |
Bolzon Bradley J PhD | Director Director | Nov 12 | Sell | 34.1 | 39,583 | 1,349,780 | 5,646,377 | 11/12/20 |
Bolzon Bradley J PhD | Director Director | Nov 10 | Sell | 33.09 | 9,400 | 311,046 | 5,681,344 | 11/10/20 |
Bolzon Bradley J PhD | Director Director | Nov 06 | Sell | 33.14 | 11,348 | 376,073 | 5,689,647 | 11/06/20 |
Roberts Christopher D. | Chief Scientific Off.. Chief Scientific Officer | Nov 04 | Option | 10.86 | 2,500 | 27,150 | 2,500 | 11/04/20 |
Roberts Christopher D. | Chief Scientific Off.. Chief Scientific Officer | Nov 04 | Sell | 31.95 | 2,500 | 79,875 | 11/04/20 | |
Epstein David M. | See Remarks See Remarks | Nov 03 | Sell | 31.5 | 12,000 | 378,000 | 711,923 | 11/03/20 |
Epstein David M. | See Remarks See Remarks | Nov 03 | Option | 6.42 | 3,000 | 19,260 | 723,923 | 11/03/20 |
Bolzon Bradley J PhD | Director Director | Oct 28 | Sell | 33.17 | 8,903 | 295,313 | 5,699,671 | 10/28/20 |
Bolzon Bradley J PhD | Director Director | Oct 20 | Sell | 33.35 | 15,746 | 525,129 | 5,707,536 | 10/20/20 |
Bolzon Bradley J PhD | Director Director | Oct 15 | Sell | 33.24 | 17,240 | 573,058 | 5,721,445 | 10/15/20 |
Bolzon Bradley J PhD | Director Director | Oct 13 | Sell | 33.43 | 22,625 | 756,354 | 5,736,674 | 10/13/20 |
Bolzon Bradley J PhD | Director Director | Oct 08 | Sell | 33.41 | 45,926 | 1,534,388 | 5,756,660 | 10/08/20 |
Hatzis-Schoch Brent | See Remarks See Remarks | Sep 16 | Option | 3.2 | 4,078 | 13,050 | 7,078 | 09/16/20 |
Hatzis-Schoch Brent | See Remarks See Remarks | Sep 16 | Sell | 31.58 | 4,078 | 128,783 | 3,000 | 09/16/20 |
Leggett Thomas | Chief Financial Offi.. Chief Financial Officer | Sep 16 | Option | 10.86 | 3,000 | 32,580 | 3,000 | 09/16/20 |
Leggett Thomas | Chief Financial Offi.. Chief Financial Officer | Sep 16 | Sell | 31 | 3,000 | 93,000 | 09/16/20 |